GSK presses court to deny Teva’s ‘skinny label’ petition

Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

SCOTUS invites govt comment on Teva clash

4 October 2022 Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.

Big Pharma

GSK signs licence deals with three generics firms to make HIV preventative for low income countries

30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Big Pharma

SCOTUS invites govt comment on Teva clash

Big Pharma

GSK signs licence deals with three generics firms to make HIV preventative for low income countries

30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

More on this story

Big Pharma

SCOTUS invites govt comment on Teva clash

Big Pharma

GSK signs licence deals with three generics firms to make HIV preventative for low income countries

30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win